Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.73 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.58 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.58 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.58 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.58 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.58 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.58 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.58 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.58 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15267699 | 0.89 | KMT2A (0.60) | POLBHDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL6414674 | 0.86 | POLB (0.71) | POLBHDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL8141144 | 0.85 | POLB (1.00) | POLBHDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL19962693 | 0.84 | POLB (0.68) | POLBHDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL12807727 | 0.83 | GAA (0.61) | POLBALDH1A1MEN1KMT2AHTT | |
| SCHEMBL11638641 | 0.83 | SMN1; SMN2 (0.59) | POLBTDP1ALDH1A1MEN1KMT2A | |
| SCHEMBL14578751 | 0.83 | POLB (0.85) | POLBHDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL23540107 | 0.81 | HDAC3 (0.70) | POLBHDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL1039601 | 0.81 | KMT2A (0.76) | TDP1ALDH1A1MEN1KMT2AHTT | |
| SCHEMBL2093671 | 0.81 | POLB (0.76) | POLBHDAC3HDAC1HDAC2HDAC10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118459362-A | N-aryl-2- (2-hydroxybenzyloxy) acetamides, preparation method and application thereof | 湖南科技大学 | 2024-08-09 | — | — | CN | disclosed |
| CN-114716344-B | 2- ((2-acetamidophenyl) amino) acetamido compound and preparation method and application thereof | 湖南科技大学 | 2023-12-22 | — | — | CN | disclosed |
| CN-117003744-A | Five-membered and six-membered compound, intermediate, preparation method, composition and application | 厦门市博瑞来医药科技有限公司 | 2023-11-07 | — | — | CN | disclosed |
| US-20230333019-A1 | TWO-PHOTON FLUORESCENT PROBES FOR SIMULTANEOUSLY DETECTING CALCIUM IONS IN ORGANELLES AND LYSOSOMAL PROTONS | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) | 2023-10-19 | — | — | US | disclosed |
| CN-114409657-B | 4-aryl (methyl) imidazoline quinoxalinone compound and preparation method and application thereof | 湖南科技大学 | 2023-02-24 | — | — | CN | disclosed |
| CN-110790724-B | Selective carbonic anhydrase inhibitor and synthesis method and application thereof | 中山大学 | 2023-01-31 | — | — | CN | disclosed |
| CN-114716344-A | 2- ((2-acetamidophenyl) amino) acetyl arylamine compound and preparation method and application thereof | 湖南科技大学 | 2022-07-08 | — | — | CN | disclosed |
| CN-114409657-A | 4-aryl (methyl) imidazoline quinoxalinone compound and preparation method and application thereof | 湖南科技大学 | 2022-04-29 | — | — | CN | disclosed |
| CN-110790724-A | Selective carbonic anhydrase inhibitor and synthesis method and application thereof | 中山大学 | 2020-02-14 | — | — | CN | disclosed |
| US-20170121344-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | SIGA TECHNOLOGIES, INC. (US) | 2017-05-04 | — | — | US | disclosed |
| US-6127544-A | 1-SUBSTITUTED-3-UREIDO-INDOLIN-2-ONES WHICH EXHIBIT SELECTIVE ANTAGONISM AGAINST GASTRIN RECEPTORS WITHOUT CAUSING SIDE EFFECTS ATTRIBUTED TO CCK-A RECEPTOR ANTAGONISM; SUCH AS FOR TREATMENT OF PEPTIC ULCERS, GASTRITIS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2000-10-03 | — | — | US | disclosed |
| US-6114536-A | ANTAGONISM AGAINST GASTRIN RECEPTORS WITHOUT CAUSING SIDE EFFECTS ATTRIBUTED TO CCK-A RECEPTOR ANTAGONISM AND ARE USEFUL FOR THE TREATMENT AND PREVENTION OF DISEASES OF DIGESTIVE ORGANS, SUCH AS PEPTIC ULCER, GASTRITIS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2000-09-05 | — | — | US | disclosed |
| WO-2000037473-A1 | EPOTHILONE DERIVATIVES AND THEIR USE AS ANTITUMOR AGENTS | NOVARTIS AG (CH) | 2000-06-29 | — | — | WO | disclosed |
| US-6031111-A | Indolin-2-one derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2000-02-29 | — | — | US | disclosed |
| CN-1046268-C | Indolin-2-one derivatives | CHUGAI PHARMACEUTICAL CO LTD (JP) | 1999-11-10 | — | — | CN | disclosed |
| US-5952511-A | EXHIBITS SELECTIVE ANTAGONISM AGAINST GASTRIN RECEPTOR WITHOUT CAUSING SIDE EFFECTS ATTRIBUTED TO GASTRIN RECEPTOR ANTAGONISM AND USEFUL FOR TREATING PEPTIC ULCER, GASTRITIS, REFLUX ESOPHAGITIS AND ZOLLINGER-ELLISON SYNDROME | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 1999-09-14 | — | — | US | disclosed |
| US-5633218-A | CONTROLLING WEEDS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1997-05-27 | — | — | US | disclosed |
| CN-1117727-A | Indolin-2-one derivative | CHUGAI PHARMACEUTICAL CO LTD (JP) | 1996-02-28 | — | — | CN | disclosed |
| EP-0685463-A1 | INDOLIN-2-ONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 1995-12-06 | — | — | EP | disclosed |
| US-5380423-A | Uranyl complex, sensitive to dihydrogen phosphate anions, fertilizer analysis | PRIVA AGRO HOLDING B.V. (NL) | 1995-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230333019-A1 | TWO-PHOTON FLUORESCENT PROBES FOR SIMULTANEOUSLY DETECTING CALCIUM IONS IN ORGANELLES AND LYSOSOMAL PROTONS | CHERP, MCU, LETM1 | POLB 4057/4885HDAC3 2446/4885HDAC1 3548/4885 |
| US-20170121344-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | TTPA, TPMT, SLC19A2 | POLB 4278/4885HDAC3 1640/4885HDAC1 2863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.